Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human anti-rabies monoclonal antibody (Keymen İlaç)
- Development stage
- Unknown
- Lead developer
- KEYMEN
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
Recombinant human anti-rabies monoclonal antibody is a biologic therapeutic developed by Keymen İlaç, a subsidiary of Alagöz Holding, for rabies post-exposure prophylaxis (PEP). As a recombinant human monoclonal antibody, it specifically targets and neutralizes the rabies virus, preventing the pathogen from infecting the central nervous system following a potential exposure, such as an animal bite. This product serves as a modern alternative to traditional blood-derived rabies immune globulins (RIG), offering a more consistent safety profile and eliminating the risks associated with human or animal-derived blood products. It is approved for use in Turkey as part of the standard PEP protocol alongside rabies vaccines.
- Other names
- Recombinant Rabies Human Monoclonal AntibodyHuman anti-rabies monoclonal antibody
02
Targets
RABV-G (Rabies virus glycoprotein)
Beyond the preview
Go deeper on recombinant human anti-rabies monoclonal antibody (Keymen İlaç).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human anti-rabies monoclonal antibody (Keymen İlaç).